Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tet...
Q1 2026
May 14, 2026
FY 2025
Mar 19, 2026
Q4 2025
Q3 2025
Nov 14, 2025
Q2 2025
Aug 13, 2025